{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T08:52:26Z","timestamp":1781513546795,"version":"3.54.1"},"reference-count":30,"publisher":"Bentham Science Publishers Ltd.","issue":"5","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CPB"],"published-print":{"date-parts":[[2026,3]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction:<\/jats:title>\n                    <jats:p>Primary Sj\u00f6gren's Syndrome (pSS) is a chronic autoimmune condition\naffecting lacrimal and salivary glands. While previous studies suggest potential associations\nbetween dyslipidemia and autoimmune diseases, the causal relationship between lipid-lowering\nmedications and pSS remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>This study employed drug-targeted Mendelian randomization (MR) analysis to assess\nthe impact of lipid-lowering drugs on pSS risk, focusing on genetic targets including HMGCR,\nPCSK9, NPC1L1, APOB, CETP, and LDLR. Data were sourced from the Global Lipids Genetics\nConsortium and UK Biobank. Significant single-nucleotide polymorphisms linked to LDL\ncholesterol were utilized as instrumental variables. Causal effects were estimated using Inverse\nVariance Weighted, Weighted Median, MR Egger, Simple Mode, and Weighted Mode methods.\nRobustness was ensured through heterogeneity and sensitivity analyses.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The inhibition of HMGCR and CETP genes was found to be significantly associated\nwith an increased risk of developing pSS (HMGCR: OR = 3.602, 95% CI [1.051, 12.344], p =\n0.041; CETP: OR = 12.251, 95% CI [2.599, 57.743], p = 0.002).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Discussion:<\/jats:title>\n                    <jats:p>HMGCR and CETP may affect pSS risk via non-lipid pathways, suggesting distinct\nmechanisms among different lipid-lowering drug targets.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>This study provides compelling evidence suggesting that lipid-lowering drugs may\ncontribute to the risk of pSS, thus offering new insights for clinical intervention strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.2174\/0113892010387265250730110805","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T04:38:53Z","timestamp":1754455133000},"page":"663-672","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Genetic Evidence for Causal Effects of Lipid-lowering Drug Targets on Primary Sj\u00f6gren's Syndrome Risk: A Mendelian Randomization Study"],"prefix":"10.2174","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-3933-879X","authenticated-orcid":true,"given":"Yuying","family":"Li","sequence":"first","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiquan","family":"Liao","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying'ao","family":"Guo","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijuan","family":"Xiao","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zaixing","family":"Qiu","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingjing","family":"Xie","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"},{"name":"Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-9599-9657","authenticated-orcid":true,"given":"Jianyong","family":"Zhang","sequence":"additional","affiliation":[{"name":"The Fourth Clinical Medical College of Guangzhou University of Chinese Medicine, Shenzhen, 518033, P.R. China"},{"name":"Department of Rheumatology, Shenzhen Traditional Chinese Medicine Hospital, Shenzhen, 518033, P.R. China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"961","DOI":"10.3390\/jpm13060961","volume":"13","author":"Mihai A.","year":"2023","unstructured":"Mihai A.; Caruntu C.; Jurcut C.; Blajut F.C.; Casian M.; Opris-Belinski D.; Ionescu R.; Caruntu A.; The spectrum of extraglandular manifestations in primary sj\u00f6gren\u2019s syndrome. J Pers Med  2023,13(6),961","journal-title":"J Pers Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"2588","DOI":"10.1093\/rheumatology\/key370","volume":"60","author":"Miyamoto S.T.","year":"2021","unstructured":"Miyamoto S.T.; Valim V.; Fisher B.A.; Health-related quality of life and costs in Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford)  2021,60(6),2588-2601","journal-title":"Rheumatology (Oxford)"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.3390\/jcm9072299","volume":"9","author":"Parisis D.","year":"2020","unstructured":"Parisis D.; Chivasso C.; Perret J.; Soyfoo M.S.; Delporte C.; Current state of knowledge on primary Sj\u00f6gren\u2019s syndrome, an autoimmune exocrinopathy. J Clin Med  2020,9(7),2299","journal-title":"J Clin Med"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/s41584-021-00605-2","volume":"17","author":"Verstappen G.M.","year":"2021","unstructured":"Verstappen G.M.; Pringle S.; Bootsma H.; Kroese F.G.M.; Epithelial\u2013immune cell interplay in primary Sj\u00f6gren syndrome salivary gland pathogenesis. Nat Rev Rheumatol  2021,17(6),333-348","journal-title":"Nat Rev Rheumatol"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"106865","DOI":"10.1016\/j.imlet.2024.106865","volume":"267","author":"Yang L.","year":"2024","unstructured":"Yang L.; Liang Y.; Pu J.; Cai L.; Gao R.; Han F.; Chang K.; Pan S.; Wu Z.; Zhang Y.; Wang Y.; Song J.; Wu H.; Tang J.; Wang X.; Dysregulated serum lipid profile is associated with inflammation and disease activity in primary Sj\u00f6gren\u2019s syndrome: A retrospective study in China. Immunol Lett  2024,267,106865","journal-title":"Immunol Lett"},{"key":"ref=6","first-page":"49","volume":"30","author":"Wang Y.","year":"2020","unstructured":"Wang Y.; Yu H.; He J.; Role of dyslipidemia in accelerating inflammation, autoimmunity, and atherosclerosis in systemic lupus erythematosus and other autoimmune diseases. Discov Med  2020,30(159),49-56","journal-title":"Discov Med"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"1124443","DOI":"10.3389\/fimmu.2023.1124443","volume":"14","author":"Li H.","year":"2023","unstructured":"Li H.; Zhan H.; Cheng L.; Huang Y.; Li X.; Yan S.; Liu Y.; Wang L.; Li Y.; Plasma lipidomics of primary biliary cholangitis and its comparison with Sj\u00f6gren\u2019s syndrome. Front Immunol  2023,14,1124443","journal-title":"Front Immunol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s40256-023-00594-5","volume":"23","author":"Michaeli D.T.","year":"2023","unstructured":"Michaeli D.T.; Michaeli J.C.; Albers S.; Boch T.; Michaeli T.; Established and emerging lipid-lowering drugs for primary and secondary cardiovascular prevention. Am J Cardiovasc Drugs  2023,23(5),477-495","journal-title":"Am J Cardiovasc Drugs"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"107614","DOI":"10.1016\/j.pharmthera.2020.107614","volume":"214","author":"Dehnavi S.","year":"2020","unstructured":"Dehnavi S.; Sohrabi N.; Sadeghi M.; Lansberg P.; Banach M.; Al-Rasadi K.; Johnston T.P.; Sahebkar A.; Statins and autoimmunity: State-of-the-art. Pharmacol Ther  2020,214,107614","journal-title":"Pharmacol Ther"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1186\/s12944-024-02181-2","volume":"23","author":"Hu X.","year":"2024","unstructured":"Hu X.; Zhang P.; Gao Y.; Ding W.W.; Cheng X.E.; Shi Q.Q.; Li S.; Zhu Y.Y.; Pan H.F.; Wang P.; Identification of lipid-modifying drug targets for autoimmune diseases: insights from drug target mendelian randomization. Lipids Health Dis  2024,23(1),193","journal-title":"Lipids Health Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"15228","DOI":"10.18632\/aging.205347","volume":"15","author":"Chen H.","year":"2023","unstructured":"Chen H.; Tang X.; Su W.; Li S.; Yang R.; Cheng H.; Zhang G.; Zhou X.; Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: A drug-target Mendelian randomization study. Aging (Albany NY)  2023,15(24),15228-15242","journal-title":"Aging (Albany NY)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1185986","DOI":"10.3389\/fneur.2023.1185986","volume":"14","author":"Qin H.","year":"2023","unstructured":"Qin H.; Yang F.; Zhao H.; Zhao J.; Lin S.; Shang Y.; Zhang C.; Hao P.; Zhang X.; Associations of lipids and lipid-lowering drugs with risk of stroke: A Mendelian randomization study. Front Neurol  2023,14,1185986","journal-title":"Front Neurol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"1383646","DOI":"10.3389\/fgene.2024.1383646","volume":"15","author":"Liu M.","year":"2024","unstructured":"Liu M.; Chen X.; Yu C.; Chen J.; Zhen P.; Liu Z.; A causal association between lipid-lowering medications and rotator cuff syndrome: A drug-targeted mendelian randomization study. Front Genet  2024,15,1383646","journal-title":"Front Genet"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"e33433","DOI":"10.1016\/j.heliyon.2024.e33433","volume":"10","author":"Tan Y.","year":"2024","unstructured":"Tan Y.; Yin J.; Wu Z.; Xiong W.; Integrative multi-omics analysis reveals cellular and molecular insights into primary Sj\u00f6gren\u2019s syndrome. Heliyon  2024,10(13),e33433","journal-title":"Heliyon"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"e0229098","DOI":"10.1371\/journal.pone.0229098","volume":"15","author":"Hayat M.","year":"2020","unstructured":"Hayat M.; Kerr R.; Bentley A.R.; Rotimi C.N.; Raal F.J.; Ramsay M.; Genetic associations between serum low LDL-cholesterol levels and variants in LDLR, APOB, PCSK9 and LDLRAP1 in African populations. PLoS One  2020,15(2),e0229098","journal-title":"PLoS One"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1007\/s10067-023-06837-9","volume":"43","author":"Qiao L.","year":"2024","unstructured":"Qiao L.; Lv S.; Meng K.; Yang J.; Genetically proxied therapeutic inhibition of lipid-lowering drug targets and risk of rheumatoid arthritis disease: A Mendelian randomization study. Clin Rheumatol  2024,43(3),939-947","journal-title":"Clin Rheumatol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"122823","DOI":"10.1016\/j.lfs.2024.122823","volume":"351","author":"Aguchem R.N.","year":"2024","unstructured":"Aguchem R.N.; Okagu I.U.; Okorigwe E.M.; Uzoechina J.O.; Nnemolisa S.C.; Ezeorba T.P.C.; Role of CETP, PCSK-9, and CYP7-alpha in cholesterol metabolism: Potential targets for natural products in managing hypercholesterolemia. Life Sci  2024,351,122823","journal-title":"Life Sci"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/imr.12891","volume":"297","author":"Anand P.K.","year":"2020","unstructured":"Anand P.K.; Lipids, inflammasomes, metabolism, and disease. Immunol Rev  2020,297(1),108-122","journal-title":"Immunol Rev"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1093\/rheumatology\/keaa456","volume":"60","author":"Lu J.","year":"2021","unstructured":"Lu J.; Guo Y.; Lu Y.; Ji W.; Lin L.; Qian W.; Chen W.; Wang J.; Lv X.; Ke M.; Kong D.; Shen Q.; Zhu Y.; Liu P.; Su J.; Wang L.; Li Y.; Gao P.; Shan J.; Liu S.; Untargeted lipidomics reveals specific lipid abnormalities in Sj\u00f6gren\u2019s syndrome. Rheumatology (Oxford)  2021,60(3),1252-1259","journal-title":"Rheumatology (Oxford)"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"979","DOI":"10.1016\/j.tcb.2020.09.006","volume":"30","author":"Yan J.","year":"2020","unstructured":"Yan J.; Horng T.; Lipid metabolism in regulation of macrophage functions. Trends Cell Biol  2020,30(12),979-989","journal-title":"Trends Cell Biol"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"1327","DOI":"10.3390\/cells11081327","volume":"11","author":"Kiran S.","year":"2022","unstructured":"Kiran S.; Rakib A.; Kodidela S.; Kumar S.; Singh U.P.; High-fat diet-induced dysregulation of immune cells correlates with macrophage phenotypes and chronic inflammation in adipose tissue. Cells  2022,11(8),1327","journal-title":"Cells"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"13229","DOI":"10.3390\/ijms232113229","volume":"23","author":"Sisto M.","year":"2022","unstructured":"Sisto M.; Ribatti D.; Lisi S.; Molecular mechanisms linking inflammation to autoimmunity in Sj\u00f6gren\u2019s syndrome: Identification of new targets. Int J Mol Sci  2022,23(21),13229","journal-title":"Int J Mol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3390\/cells11060970","volume":"11","author":"Williams M.J.","year":"2022","unstructured":"Williams M.J.; Alsehli A.M.; Gartner S.N.; Clemensson L.E.; Liao S.; Eriksson A.; Isgrove K.; Thelander L.; Khan Z.; Itskov P.M.; Moulin T.C.; Ambrosi V.; Al-Sabri M.H.; Lagunas-Rangel F.A.; Olszewski P.K.; Schi\u00f6th H.B.; The statin target HMGCR regulates energy metabolism and food intake through central mechanisms. Cells  2022,11(6),970","journal-title":"Cells"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"727","DOI":"10.3390\/ph14080727","volume":"14","author":"Voss L.","year":"2021","unstructured":"Voss L.; Guttek K.; Reddig A.; Reinhold A.; Voss M.; Simeoni L.; Schraven B.; Reinhold D.; Pitavastatin is a highly potent inhibitor of T-cell proliferation. Pharmaceuticals  2021,14(8),727","journal-title":"Pharmaceuticals"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/vaccines8020272","volume":"8","author":"Rizzo C.","year":"2020","unstructured":"Rizzo C.; Grasso G.; Destro Castaniti G.M.; Ciccia F.; Guggino G.; Primary Sjogren syndrome: Focus on innate immune cells and inflammation. Vaccines  2020,8(2),272","journal-title":"Vaccines"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"2919","DOI":"10.1093\/cvr\/cvab350","volume":"118","author":"Nurmohamed N.S.","year":"2022","unstructured":"Nurmohamed N.S.; Ditmarsch M.; Kastelein J.J.P.; Cholesteryl ester transfer protein inhibitors: From high-density lipoprotein cholesterol to low-density lipoprotein cholesterol lowering agents? Cardiovasc Res  2022,118(14),2919-2931","journal-title":"Cardiovasc Res"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"106972","DOI":"10.1016\/j.phrs.2023.106972","volume":"197","author":"Mehta N.","year":"2023","unstructured":"Mehta N.; Dangas K.; Ditmarsch M.; Rensen P.C.N.; Dicklin M.R.; Kastelein J.J.P.; The evolving role of cholesteryl ester transfer protein inhibition beyond cardiovascular disease. Pharmacol Res  2023,197,106972","journal-title":"Pharmacol Res"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.3390\/antiox11091734","volume":"11","author":"Dorighello G.G.","year":"2022","unstructured":"Dorighello G.G.; Assis L.H.P.; Rentz T.; Morari J.; Santana M.F.M.; Passarelli M.; Ridgway N.D.; Vercesi A.E.; Oliveira H.C.F.; Novel role of CETP in macrophages: Reduction of mitochondrial oxidants production and modulation of cell immune-metabolic profile. Antioxidants  2022,11(9),1734","journal-title":"Antioxidants"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.3390\/cells10051061","volume":"10","author":"Bonacina F.","year":"2021","unstructured":"Bonacina F.; Pirillo A.; Catapano A.L.; Norata G.D.; HDL in immune-inflammatory responses: Implications beyond cardiovascular diseases. Cells  2021,10(5),1061","journal-title":"Cells"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1038\/s41584-023-00932-6","volume":"19","author":"Thorlacius G.E.","year":"2023","unstructured":"Thorlacius G.E.; Bj\u00f6rk A.; Wahren-Herlenius M.; Genetics and epigenetics of primary Sj\u00f6gren syndrome: Implications for future therapies. Nat Rev Rheumatol  2023,19(5),288-306","journal-title":"Nat Rev Rheumatol"}],"container-title":["Current Pharmaceutical Biotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010387265250730110805","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/244217\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/article\/download?doi=10.2174\/0113892010387265250730110805","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T07:56:48Z","timestamp":1781510208000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/244217\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/0113892010387265250730110805","relation":{},"ISSN":["1389-2010"],"issn-type":[{"value":"1389-2010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Double blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2025-02-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-06","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-05-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}